FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

PRINCETON, N.J.--(BUSINESS WIRE) May 26, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) given with two cycles of platinum-doublet chemotherapy...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news